

# Prognostic Value of Systemic Immune-Inflammation Index (SII), Platelet-Lymphocyte Ratio (PLR) and Neutrophil-Lymphocyte Ratio (NLR) in Predicting Mortality in Pneumosepsis Patients in Intensive Care Unit

## Yoğun Bakım Ünitesinde Pnömozeptis Hastalarında Mortaliteyi Öngörmeye Sistemik İmmün-İnflamasyon İndeksi (SII), Trombosit-Lenfosit Oranı (PLR) ve Nötrofil-Lenfosit Oranının (NLR) Prognostik Değeri

Kamuran ULUÇ<sup>1</sup> , Hamdiye TURAN<sup>2</sup> 

<sup>1</sup>Department of Intensive Care, Muş State Hospital, Muş, TÜRKİYE

<sup>2</sup>Harran University Faculty Of Medicine Chest Diseases Department, Şanlıurfa, TÜRKİYE

### Abstract

**Background:** This study aims to evaluate the prognostic value of Systemic Immune-Inflammation Index (SII), Platelet-Lymphocyte Ratio (PLR) and Neutrophil-Lymphocyte Ratio (NLR) to predict mortality in patients with pneumosepsis in the intensive care unit (ICU).

**Materials and Methods:** The study was conducted retrospectively and clinical data of patients diagnosed with pneumosepsis were analyzed. Age, gender, comorbidities, length of stay (LOS) in the ICU, Sequential Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, SII, PLR, NLR values and prognoses were obtained from patient files and hospital records system.

**Results:** A total of 68 patients were included in the study. 60.3% of the patients were male and 39.7% were female. The mean age of deceased patients was statistically significantly higher than that of discharged patients ( $p = 0.016$ ). In the study, 22 patients were discharged and 46 patients died. While the mean SII value was  $464.05 \pm 107.31$  in the discharged group, this value was  $845.53 \pm 111.04$  in those who died ( $p < 0.001$ ). Similarly, the PLR value was  $88.14 \pm 10.66$  in those discharged and  $114.89 \pm 12.97$  in those who died ( $p < 0.001$ ). The NLR value was  $3.5 \pm 0.86$  in the discharged group and  $6.73 \pm 0.84$  in the deceased group ( $p < 0.001$ ).

**Conclusions:** This study reveals that SII, NLR and PLR indices are important and reliable indicators for predicting mortality in pneumosepsis patients in the ICU.

**Keywords:** Systemic immune-inflammation index, Platelet/lymphocyte ratio, Neutrophil/lymphocyte ratio, Pneumosepsis, Intensive care unit

### Öz

**Amaç:** Bu çalışma, pnömozeptis tanısı almış hastalarda yoğun bakım ünitesinde mortaliteyi öngörmek amacıyla Sistemik İmmün-İnflamasyon İndeksi (SII), Trombosit-Lenfosit Oranı (PLR) ve Nötrofil-Lenfosit Oranı'nın (NLR) prognostik değerini değerlendirmeyi amaçlamaktadır.

**Materyal ve Metod:** Çalışma retrospektif olarak gerçekleştirilmiş ve pnömozeptis tanısı almış hastaların klinik verileri analiz edilmiştir. Hastaların yaşı, cinsiyeti, eşlik eden hastalıkları, yoğun bakımda kalış süresi, Sıralı Organ Yetmezliği Değerlendirmesi (SOFA) skoru, Akut Fizyoloji ve Kronik Sağlık Değerlendirmesi II (APACHE II) skoru, SII, PLR, NLR değerleri ve prognozları hasta dosyaları ve hastane kayıt sisteminden elde edilerek kaydedilmiştir.

**Bulgular:** Çalışmaya toplam 68 hasta dahil edilmiştir. Hastaların %60,3'ü erkek, %39,7'si kadındır. Hayatını kaybeden hastaların yaş ortalaması, taburcu edilen hastalara kıyasla istatistiksel olarak anlamlı şekilde daha yüksek bulunmuştur ( $p = 0,016$ ). Çalışmada 22 hasta taburcu edilirken, 46 hasta hayatını kaybetmiştir. Taburcu edilen grupta ortalama SII değeri  $464,05 \pm 107,31$  iken, hayatını kaybedenlerde bu değer  $845,53 \pm 111,04$  olarak tespit edilmiştir ( $p < 0,001$ ). Benzer şekilde PLR değeri taburcu edilenlerde  $88,14 \pm 10,66$ , hayatını kaybedenlerde ise  $114,89 \pm 12,97$ 'dir ( $p < 0,001$ ). NLR değeri ise taburcu edilen grupta  $3,5 \pm 0,86$  hayatını kaybeden grupta  $6,73 \pm 0,84$  olarak bulunmuştur ( $p < 0,001$ ).

**Sonuç:** Bu çalışma, yoğun bakım ünitesindeki pnömozeptis hastalarında SII, NLR ve PLR indekslerinin mortaliteyi öngörmeye önemli ve güvenilir göstergeler olduğunu ortaya koymaktadır.

**Anahtar Kelimeler:** Sistemik immün-inflamasyon indeks, Trombosit/lenfosit oranı, Nötrofil/lenfosit oranı, Pnömozeptis, Yoğun bakım ünitesi

### Corresponding Author / Sorumlu Yazar

Dr. Kamuran ULUÇ

Department of Intensive Care, Muş State Hospital, Muş, TÜRKİYE

E-mail: kamuranuluc@hotmail.com

Received / Geliş tarihi: 11.11.2024

Accepted / Kabul tarihi: 09.12.2024

DOI: 10.35440/hutfd.1583285

## Introduction

Sepsis is a life-threatening organ dysfunction caused by the host's response to infection. Sepsis and septic shock are major global health concerns, affecting millions and causing high mortality rates worldwide. Early diagnosis and treatment within the first hours of sepsis onset significantly improve the survival chances of the patient (1–3).

Pneumonia is defined as an acute infectious process in the lung parenchyma and represents the most common cause of infection-related mortality globally. It also contributes significantly to morbidity, particularly in critically ill patients with comorbidities, potentially leading to sepsis and septic shock (4,5). Pneumonia is a primary cause of sepsis. Research indicates that pneumonia-induced sepsis is associated with higher mortality rates compared to sepsis from other infection sources (6).

For sepsis patients, identifying biomarkers that predict mortality, facilitating early diagnosis and treatment, and exploring factors that yield favorable clinical outcomes are critical (7, 8).

The Systemic Immune-Inflammation Index (SII), a novel biomarker based on platelet, lymphocyte, and neutrophil counts, was introduced in 2014 (9). The Neutrophil-Lymphocyte Ratio (NLR) and Platelet-Lymphocyte Ratio (PLR), additional inflammatory biomarkers, may serve as indicators of sepsis onset. A hematological profile can also be employed to assess therapy response and detect early signs of infection. Sepsis is one of the conditions in which PLR and NLR are utilized as predictive indices (10).

Our study aimed to evaluate the utility of SII, PLR, and NLR in predicting pneumosepsis mortality.

## Materials and Methods


This retrospective study was approved by the Ethics Committee of Health Sciences University Diyarbakır Gazi Yaşargil Training and Research Hospital (Approval no: 2024/187). The study was conducted in accordance with the Declaration of Helsinki. Our study included patients admitted to the ICU between January 2018 and February 2020 and diagnosed with pneumosepsis. Patients who were older than eighteen years of age, clinically, laboratory and radiologically diagnosed with pneumosepsis and whose data were not missing were included in the study. Patients who were younger than 18 years of age, who were not diagnosed with pneumosepsis and whose data were incomplete were excluded (Figure 1). Patient demographics (age, gender), comorbidities, length of stay (LOS) in the ICU, Sequential Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, SII, PLR, NLR values, and prognoses (discharged or deceased) were recorded from patient files and hospital records.

Scoring systems are important tools used to predict disease severity and mortality in intensive care patients, including patients with sepsis. They are also useful for standardizing research in ICUs and comparing the quality of patient care. The APACHE II scoring system is one of the most

widely used systems in the world. The APACHE II system consists of three parts: the acute physiology score, age, and chronic health assessment. In this way, the acute and chronic health status of the patient is evaluated (11). The SOFA scoring system is used to diagnose and predict outcomes for patients with sepsis in the ICU. The SOFA scoring system calculates a severity score using straightforward measurements of major organ dysfunctions without considering any parameters related to the patient's chronic health status (12).

The SII was calculated as follows:  $SII = \text{neutrophil count } (10^9/L) \times \text{platelet count } (10^9/L) / \text{lymphocyte count } (10^9/L)$  (9).

The diagnosis of sepsis was established according to the Sepsis-3 criteria, and pneumonia was diagnosed based on the American Thoracic Society guidelines (13,14).



**Figure 1.** Flow chart showing patient flow

## Statistical Analysis

Statistical analyses were performed using SPSS software version 22.0 (SPSS Inc., Chicago, IL). Descriptive statistics of continuous variables were expressed as mean and standard deviation, and categorical variables were expressed as frequency (n) and percentage (%). Student's t test or Mann-Whitney U test was applied for comparisons of continuous variables between groups, depending on whether the data conformed to normal distribution. Chi-square test and Fisher's exact test were used to compare categorical variables between groups. ROC analysis was performed to evaluate SII, PLR, NLR and other parameters in predicting mortality in pneumosepsis. Multivariate logistic regression analysis was performed to identify factors associated with mortality. A value of  $p < 0.05$  was accepted as the limit of statistical significance.

**Results**

Of the 68 patients, 60.3% were male and 39.7% were female. Twenty-two patients were discharged, while 46 died. The average age of discharged patients was 54.82±8.17 years, while the average age of deceased patients was 61.24±10.81

years. This difference was statistically significant (p = 0.016). The LOS ICU was 14.18±6.12 days for discharged patients and 22.37±15.48 days for deceased patients. This difference was also statistically significant (p = 0.019) (Table 1).

**Table 1.** Demographic characteristics of the patients

	All patients (n = 68)	Discharged (n = 22)	Deceased (n = 46)	p value
<b>Gender (n %)</b>	41 (60.3%) Male 27 (39.7%) Female	13(59.1%) Male 9(40.9%) Female	28(60.9%) Male 18(39.1%)Female	0.901
<b>Age (years)</b>	59.16 ± 10.42	54.82 ± 8.17	61.24 ± 10.81	0.016
<b>Comorbidities</b>				
<i>Hypertension</i>	21(30.8%)	6 (27.2%)	15 (32.6%)	0.065
<i>Diabetes</i>	14(20.5%)	8 (36.4%)	6 (13%)	<0.001
<i>Neurological disease</i>	7 (10.3%)	2 (9.1%)	5 (10.9%)	0.832
<i>Chronic pulmonary diseases</i>	17 (25%)	5 (22.7%)	12 (26.1%)	0.371
<i>Cardiac disease</i>	16 (23.5%)	6 (27.2%)	10 (21.7%)	0.365
<i>Chronic kidney diseases</i>	15 (22.1%)	4 (18.2%)	11 (23.9%)	0.062
<i>Chronic liver disease</i>	9 (13.2%)	3 (13.6%)	6 (13%)	0.901
<i>Malignancy</i>	4 (5.9%)	1 (4.5%)	3 (6.5%)	0.633
<b>LOS ICU</b>	19.72±13.7	14.18±6.12	22.37±15.48	<0.001
<b>SOFA</b>	8.94±3.22	5.18±1.92	10.74±1.88	<0.001
<b>APACHE II</b>	27.84±9.37	19.64±4.48	31.76±8.53	<0.001
<b>PLR</b>	106.1±17.57	88.14±10.66	114.89±12.97	<0.001
<b>NLR</b>	5.69±1.74	3.5±0.86	6.73±0.84	<0.001
<b>SII</b>	722.11±210.28	464.05±107.31	845.53±111.04	<0.001

n: Number of patients. %: Percentage. SOFA: Sequential Organ Failure Assessment. APACHE II: Acute Physiology and Chronic Health Evaluation II. LOS: Length of stay. ICU: Intensive care unit. NLR:Neutrophil-Lymphocyte Ratio. PLR: Platelet-Lymphocyte Ratio. SII: Systemic Immune-Inflammation Index

In the discharged group, the mean SII was 464.05 ± 107.31, while it was 845.53 ± 111.04 in the deceased group (p<0.001). The PLR was 88.14 ± 10.66 in the discharged group and 114.89 ± 12.97 in the deceased group (p<0.001). The mean NLR was 3.5 ± 0.86 in the discharged group and 6.73 ± 0.84 in the deceased group (p<0.001).

The results of multivariate logistic regression analysis of the


variables associated with mortality in the study are presented in Table 2.

The ROC analysis results for SII, PLR, and NLR parameters in predicting mortality in pneumosepsis are presented in Figure 2, while the ROC analysis results for age, LOS ICU, SOFA score, and APACHE II score are shown in Figure 3.


**Table 2.** Multivariate logistic regression analyses to examine the association between mortality and statistically significant variables of the study

	p value	HR	95% CI	
			Lower	Upper
<b>SOFA</b>	<0.001	1.085	1.007	1.196
<b>APACHE II</b>	<0.001	1.052	1.015	1.198
<b>LOS ICU</b>	<0.001	1.053	1.008	1.062
<b>PLR</b>	<0.001	1.001	1.000	1.002
<b>NLR</b>	<0.001	1.060	1.034	1.083
<b>SII</b>	<0.001	1.004	1.001	1.007

SOFA: Sequential Organ Failure Assessment. APACHE II: Acute Physiology and Chronic Health Evaluation II. LOS: Length of stay. ICU: Intensive care unit. PLR: Platelet-Lymphocyte Ratio. NLR:Neutrophil-Lymphocyte Ratio. SII: Systemic Immune-Inflammation Index. HR: Hazard ratio. 95% CI: 95% Confidence interval.



**Figure 2.** Comparison of the effects of SII, PLR, and NLR values on mortality using ROC curves and AUC values



**Figure 3.** Comparison of the effects of Age, LOS ICU, SOFA score, and APACHE II score on mortality using ROC curves and AUC values

## Discussion

The Systemic Immune-Inflammation Index (SII) has been defined as a prognostic biomarker for various diseases, as it reflects the balance of inflammatory, immune, and thrombotic pathways in patients by combining three predictive indicators. Initially, it was identified as a prognostic indicator in patients with resected hepatocellular carcinoma, based on early studies (9).

In a study of 242 patients (128 with sepsis, mean age 70.1 years and 114 without sepsis, mean age 69.7 years), the mean SII was  $4444.06 \times 10^9$  in patients with sepsis and  $3013.94 \times 10^9$  in patients without sepsis (15). A statistically significant correlation between SII and sepsis was shown. Mangalesh et al. reported that among 267 patients with sepsis, the SII, PLR, and NLR values were statistically significant in the discharged and deceased patient groups (16). Another study showed that inflammatory parameters, such as SII and NLR, are associated with disease severity and can potentially serve as important risk factors in the progression of COVID-19 (17). In our study, the SII, PLR, and NLR values were statistically significant in predicting mortality in pneumosepsis patients and were consistent with findings in the literature. In this study of 16,007 individuals from a cohort of critically ill patients with sepsis in the MIMIC database, the results of the analysis showed a J-shaped relationship between SII and short-term mortality, with low and high levels associated with an increased hazard. The SII level with the lowest 28-day mortality risk was  $774.46 \times 10^9/L$ . Therefore, a lower SII theoretically indicates that the body may be impaired by severe inflammation or myelosuppression and may generally be associated with a poor prognosis (18). In our study, elevated SII was found to be associated with mortality in pneumosepsis patients and these results are consistent with other literature supporting the use of SII as a prognostic indicator in sepsis patients.

The SII has also been used to evaluate clinical outcomes in various types of cancer, predict mortality in patients with infective endocarditis, estimate respiratory failure in Guillain-Barré syndrome, and assess mortality risk in acute or subacute sinus vein thrombosis (19–22).

To lower the morbidity and mortality linked to sepsis, risk stratification is crucial for directing early identification and treatment. Because of their relative accessibility and the availability of hemogram data, NLR and PLR have long been utilized as predictors of morbidity and mortality in cardiovascular illnesses, malignancies, and sepsis. NLR levels have been found to be higher in sepsis and septic shock in a number of investigations (16). Similarly, our study observed that high NLR and PLR levels were associated with mortality in pneumosepsis patients, supporting the prognostic value of these biomarkers.

One study reported that the NLR outperformed conventional infection indicators in predicting bacteremia (23). Numerous investigations have documented the effectiveness of the NLR in predicting severity and mortality in critically ill and septic patients (24). The prognostic significance of the

PLR and NLR in SARS-CoV-2 infections has been clarified in recent studies (25). PLR is also utilized to predict sepsis mortality, illness severity, and diagnosis (26). The results of our investigation, which associate mortality in pneumosepsis patients with elevated NLR and PLR levels, are consistent with findings from previous research.

## Limitations

The primary limitations of this study include its retrospective design and its limited sample size. As a retrospective study, this research may be prone to missing data, which could restrict the generalizability of the results. Additionally, the limited sample size hinders the ability to draw broader conclusions about the population. Therefore, larger and more diverse prospective studies are required to produce more reliable and generalizable results.

## Conclusion

This study demonstrates that inflammatory biomarkers, particularly the SII, NLR, and PLR, play a significant role in predicting mortality in pneumosepsis patients. These biomarkers are easily accessible and reliable indicators for determining the prognosis of pneumosepsis patients in the ICU. Future studies should evaluate and validate the potential use of these biomarkers for monitoring treatment responses in larger patient populations.

---

**Ethical Approval:** The Diyarbakır Gazi Yaşargil Training and Research Hospital Ethics Committee gave its approval for the study to be conducted (Approval no: 2024/187).

---

### Author Contributions:

Concept: K.U., H.T.

Literature Review: K.U., H.T.

Design: K.U., H.T.

Data acquisition: K.U.

Analysis and interpretation: K.U., H.T.

Writing manuscript: K.U., H.T.

Critical revision of manuscript: K.U., H.T.

**Conflict of Interest:** The authors have no conflicts of interest to declare.

**Financial Disclosure:** Authors declared no financial support.

---

## References

- Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med.* 2021;47(11):1181–247.
- Fleischmann-Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. *Intensive Care Med.* 2020;46(8):1552–562.
- Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. *JAMA.* 2017;318(13):1241–249.
- Marrie TJ, Huang JQ. Epidemiology of community-acquired

- pneumonia in Edmonton, Alberta: An emergency department-based study. *Can Respir J*. 2005;12(3):139-42.
5. Campling J, Jones D, Chalmers J, Jiang Q, Vyse A, Madhava H, et al. Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England. *BMJ Open Respir Res*. 2020;7(1):e000703.
  6. Kim WY, Lee YJ, Yeon Lim S, Ok Koh S, Choi WI, Chan Kim S, et al. Clinical characteristics and prognosis of pneumonia and sepsis: Multicenter study. *Minerva Anestesiol*. 2013;79(12):1365-65.
  7. Fulton II MR, Zubair M, Taghavi S. Laboratory Evaluation of Sepsis. *StatPearls*. 2024.
  8. Erdoğan M, Findikli HA. Prognostic value of the lactate/albumin ratio for predicting mortality in patients with pneumosepsis in intensive care units. *Medicine (United States)*. 2022;101(4):e28748.
  9. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res*. 2014;20(23):6212-22.
  10. Lengkong WY, Iskandar A. Gambaran Platelet-To-Lymphocyte Ratio (Plr) Pada Sepsis Dan Syok Septik. *CHMK Health Journal*. 2020;4(3):222-26.
  11. Ho KM, Dobb GJ, Knuihan M, Finn J, Lee KY, Webb SA. A comparison of admission and worst 24-hour Acute Physiology and Chronic Health Evaluation II scores in predicting hospital mortality: a retrospective cohort study. *Crit Care*. 2006;10(1):R4.
  12. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. *Crit Care Med*. 1998;26:1793-800.
  13. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*. 2019;200(7):e45-e67.
  14. Singer M, Deutschman CS, Seymour C, Shankar-Hari M, Anane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA*. 2016;315(8):801-10.
  15. Lagunas-Alvarado M, Mijangos-Huesca FJ, Terán-González JO, Lagunas-Alvarado MG, Martínez-Zavala N, Reyes-Franco I, et al. Índice de inmunidad-inflamación sistémica en sepsis. *Med Int Méx*. 2017;33(3):303-9.
  16. Mangalesh S, Dudani S, Malik A. The systemic immune-inflammation index in predicting sepsis mortality. *Postgrad Med*. 2023;135(4):345-51.
  17. Acar E, Demir A, Yıldırım B, Kaya MG, Gökçek K. The role of hemogram parameters and C-reactive protein in predicting mortality in COVID-19 infection. *Int J Clin Pract*. 2021;75(7):e14256.
  18. Jiang D, Bian T, Shen Y, Huang Z. Association between admission systemic immune-inflammation index and mortality in critically ill patients with sepsis: a retrospective cohort study based on MIMIC-IV database. *Clin Exp Med*. 2023;23(7):3641-50.
  19. Li X, Gu L, Chen Y, Chong Y, Wang X, Guo P, et al. Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis. *Ann Med*. 2021;53(1):1827-38.
  20. Wu X, Wang H, Xie G, Lin S, Ji C. Increased systemic immune-inflammation index can predict respiratory failure in patients with Guillain-Barré syndrome. *Neurol Sci*. 2022;43(2):1223-31.
  21. Agus HZ, Kahraman S, Arslan C, Yildirim C, Erturk M, Kalkan AK, et al. Systemic immune-inflammation index predicts mortality in infective endocarditis. *J Saudi Heart Assoc*. 2020;32(1):58-64.
  22. Li S, Liu K, Gao Y, Zhao L, Zhang R, Fang H, et al. Prognostic value of systemic immune-inflammation index in acute/subacute patients with cerebral venous sinus thrombosis. *Stroke Vasc Neurol*. 2020;5(4):368-73.
  23. de Jager CPC, van Wijk PTL, Mathoera RB, de Jongh-Leuvenink J, van der Poll T, Wever PC. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. *Crit Care*. 2010;14(5):R192.
  24. Huang Z, Fu Z, Huang W, Huang K. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. *Am J Emerg Med*. 2020;38(3):641-47.
  25. Chen F, Fang Z, Zhong M, Liu Y, Zhang Y, Zhang K, Su D, Zhen, et al. The characteristics and outcomes of 681 severe cases with COVID-19 in China. *J Crit Care*. 2020;60:32-7.
  26. Shen Y, Huang X, Zhang W. Platelet-to-lymphocyte ratio as a prognostic predictor of mortality for sepsis: Interaction effect with disease severity - A retrospective study. *BMJ Open*. 2019;9(1):e022896.